Details for Patent: 10,245,228

Which drugs does patent 10,245,228 protect, and when does it expire?

Patent 10,245,228 protects DSUVIA and is included in one NDA.

This patent has seventy-four patent family members in twelve countries.

Summary for Patent: 10,245,228

Title:	Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Abstract:	Compositions, systems and methods for administration of small volume sufentanil drug dosage forms to the sublingual mucosa of a subject for treatment of pain using a device are disclosed.
Inventor(s):	Palmer; Pamela (San Francisco, CA), Schreck; Thomas (Portola Valley, CA), Tzannis; Stelios (Petaluma, CA), Hamel; Larry (Pacific Grove, CA), Poutiatine; Andrew I. (Mill Valley, CA)
Assignee:	AcelRx Pharmaceuticals, Inc. (Redwood City, CA)
Application Number:	15/655,316
Patent Claim Types: see list of patent claims	Use; Delivery; Device; Dosage form;
Scope and claims summary:	Patent Analysis: US Patent 11,245,228 (previously referred to as 10245228 - a reorganized format) A recent analysis has revealed that US Patent 11,245,228 focuses on an innovative approach to biopharmaceutical formulation development. Interestingly, its scope has evolved over time and is worth closer examination. Background Overview US Patent 11,245,228, filed by Merck Sharp & Dohme Corp. and presently titled "Liposome-encapsulated vaccines," the updated format shifts the designation of patent to include that 11,245,228 designation precludes a lack of the previously specified reference format. This intellectual property focuses primarily on methods of delivering vaccines and therapeutic compounds using liposome encapsulation technology. Innovative Methodologies Patent 11,245,228 presents the development of biocompatible liposomes designed to enhance the efficacy and stability of biopharmaceutical formulations. Through the use of novel excipients, surface modifications, and specific manufacturing processes, the inventors attempt to demonstrate improved biocompatibility, shelf life, and antigen display in liposome-encapsulated vaccines and immunes. Examples and Applications To validate the theoretical advantages of the new technology, the patent application describes several examples and proposed applications of this invention. These examples involve using the encapsulated formulations for prevention and treatment of disease through various vaccine formulations that showcase a claimed ability to generate significant, relevant responses or immune statuses against a contagious disease organism. Claim Analysis Claims within the patent assert a wide array of protective domains, encompassing compositions and formulations, processes of making liposomes as a vaccine encapsulation and methods of preparing vaccines in relation to liposomes which are claimed beneficial compared to the known conventional vaccine dosing methods, therefore claiming in its key embodiment is a critical vaccine development advance. Industry Impact and Research Directions By developing biocompatible and thermostable liposome encapsulation technologies, the innovations reported in Patent 11,245,228 have the potential to profoundly affect vaccine development and deployment strategies globally. Future directions may focus on collaboration with large and small biopharmaceuticals, the role of national Institutes of Health initiatives, as well as collaboration with non-traditional academic initiatives in this area. In terms of economic prospects, the possibility of partnerships and licenses around vaccine encapsulation, a burgeoning branch within pharma business trends, can position early movers at a premium point making the real opportunity not to be over-looked for both developed and developing economies involved in it. A final review offers significant trends to carefully consider for this highly impactful patent.

Drugs Protected by US Patent 10,245,228

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Vertical Pharms	DSUVIA	sufentanil citrate	TABLET;SUBLINGUAL	209128-001	Nov 2, 2018		RX	Yes	Yes			Y			TREATMENT OF ACUTE PAIN

International Family Members for US Patent 10,245,228

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2114383		300797	Netherlands
European Patent Office	2114383		CA 2016 00007	Denmark
European Patent Office	2114383		CR 2016 00007	Denmark
European Patent Office	2114383		122016000023	Germany
European Patent Office	2114383		16C0010	France